Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.75 |
| ▸ | SRC | P12931 | 4/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.73 |
| ▸ | KIT | P10721 | 2/20 | 0.73 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | FYN | P06241 | 2/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | MET | P08581 | 2/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.73 |
| ▸ | LTK | P29376 | 2/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.73 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.73 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.73 |
| ▸ | BTK | Q06187 | 2/20 | 0.73 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.73 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.73 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23450870 | 0.96 | EGFR (0.70) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL7237234 | 0.92 | EGFR (0.72) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL24751920 | 0.90 | EGFR (0.65) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL8525840 | 0.90 | EGFR (0.64) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL23451101 | 0.90 | EGFR (0.73) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL23450792 | 0.89 | EGFR (0.69) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL23450802 | 0.89 | EGFR (0.65) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL23450989 | 0.89 | EGFR (0.60) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL23450986 | 0.87 | SRC (0.61) | EGFRERBB2SRCERBB4KIT | |
| SCHEMBL25270067 | 0.87 | EGFR (0.80) | EGFRERBB2SRCERBB4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-6562818-B1 | For treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis | WARNER-LAMBERT COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6127374-A | AN ENZYME INHIBITOR FOR TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS AND PSORIASIS | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885SRC 6/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885SRC 6/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.